A review on liposomal amphotericin b in antifungal therapy

Tirupathi Reddy A; venkateshwara Reddy Basu; Ganesh A; Asiya fathema D; Usha V; Sai Sandhya M

doi:10.46956/ijihd.v6i6.256

A.Tirupathi Reddy Associate Professor, Sankar Reddy Institute of pharmaceutical Sciences, Salakaveedu(V), Bestavaripeta (M), Prakasam (D), Pincode-523370
Basu venkateshwara Reddy Professor, Sankar Reddy Institute of Pharmaceutical Sciences, Salakalaveedu(V),Bestavaripeta (M), Prakasam (D), Pincode-523370
A.Ganesh B. Pharmacy, Sankar Reddy Institute of Pharmaceutical Sciences, Salakalaveedu (V), Bestavaripeta (M), Prakasam (D), Pincode- 523370
D. Asiya fathema B. Pharmacy, Sankar Reddy Institute of Pharmaceutical Sciences, Salakalaveedu (V), Bestavaripeta (M), Prakasam (D), Pincode- 523370
V. Usha B. Pharmacy, Sankar Reddy Institute of Pharmaceutical Sciences, Salakalaveedu (V), Bestavaripeta (M), Prakasam (D), Pincode- 523370
M. Sai Sandhya B. Pharmacy, Sankar Reddy Institute of Pharmaceutical Sciences, Salakalaveedu (V), Bestavaripeta (M), Prakasam (D), Pincode- 523370

DOI https://doi.org/10.46956/ijihd.v6i6.256

Abstract

To reduce the in-vivo toxicity of the broad-spectrum antifungal drug amphotericin B, various lipid formulations of amphotericin B, ranging from lipid complexes to small unilamellar liposomes, have been developed and subsequently commercialized. These structurally diverse formulations differ in their serum pharmacokinetics as well as their tissue localization, tissue retention, and toxicity. This difference can affect the choice of formulation for a given infection, the time of initiation of treatment, and the dosing regimen. Although preclinical studies have shown similarities in the in-vitro and in-vivo antifungal activity of the formulations with comparable dosing, their acute, and chronic toxicity. Profiles are not the same, and this has a significant impact on their therapeutic indices, especially in high-risk, immunosuppressed patients. With the recent introduction of new antifungal drugs to treat the increasing numbers of infected patients, the amphotericin B lipid formulations are now being studied to evaluate their potential in combinational drug regimens. With proven efficacy demonstrated during the past decade, it is expected that amphotericin B lipid formulations will remain an important part of antifungal drug therapy.

Keywords: in-vivo toxicity, preclinical studies, immunosuppressed patients

Downloads

Download data is not yet available.

References

1. D Ellis Amphotericin B: spectrum and resistance J Antimicrob chemother, 49 (suppl 1) (2002), pp. 7-10.
2. NA Kshirsagar, SK pandya, GB Kirodian, S Sanath Liposomal drug delivery system from laboratory to clinic J Postgard Med, 51 (suppl 1) (2005),PP. S5-S15.
3. MA Hossain, S Maesaki, H Kakeya, et al.Efficacy of NS-718, a novel lipid nanosphere – encapsulated amphotericin B, against Cryptococcus neoformans Antimicrob Agents Chemother, 42 (1998),pp.1722-1725.
4. MD Richardson, DW Warnock Fungal Infection: Diagnosis and Management, Blackwell scientific publications, Oxford (1993) Jp Utz, JE Bennett, NW Brandriss, WT Butler, GJ Hill.
5. Amphotericin B toxicity. Combined clinical staff conference at the national institutes of health Ann Intern Med, 61 (1964), pp. 334-354MS Maddux, SL Barriere.
6. A review of complication of amphotericin B therapy: recommendations for prevention and management Drug intelligents clin pharmacy, 14 (1980), pp. 177-181.
7. JR Starke, EO Mason Jr, WG Kramer, SL Kaplan Pharmacokinetics of amphotericin b in infants and children J Infect Dis, 155 (4) (1987), pp. 766-774.
8. Alving C.R. Macrophages, as targets for delivery of liposome encapsulated antimicrobial agents. Adv Drug Delivery Rev, (1998); 2.
9. C. j. Chapman Allison, A.C., Gregoriadis, G, 1974. Liposomes as immunological adjuvant. Nature 252, 252.
10. Christine D. Waugh, in x Pharm: The Comprehensive Pharmacology Reference, 2007.
11. Winged JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, et al. A randomized, double-blind comparative trail evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ ABLC Collaborative study group. Clin infect Dis. 2000 Nov; (5):1155-63.
12. Serrano, D.R; Hernandez, L.; Fleire, L.; Gonzalez-Alvarez, I.; Montoya ,A.; Ballesteros, M.P.; Dea-Ayuleva, MA.; Miro, G.; Bolas-Fernandez, F.; Torrado,J.J. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulation. Int. J. Pharm. 2013, 447, 38-46.
13. Tilley, J.C. Clinicla efficacy of amphotericin B lotion I the treatment of various cutaneous monilial infections. J.La. State Med. Soc. Off. Organ La. State Med. Soc. 1962, 114, 433-435.
14. Hamill RJ. Amphotericin formulations: a comparative review of efficacy and toxicity. Drugs.2013 Jun; 73(9):919-34.
15. Alder-Moore JP, Proffitt RT. Amphotericin lipid preparations: What are differences? Clin Microbial infect. 2008 May; 14 (suppl 4); 25-36.
16. Mahfoozur Rahman, Vikas Kumar,in nanotechnology- Based Approaches for Targeting and Delivery of Drugs and Genes,2017.